Resistant Hypertension

Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave

by Prateek Chopra | June 20, 2026 | Cardiology Conferences | ESH 2026 Therapeutic Context: Renal denervation (RDN) is emerging as a third pillar of hypertension management, alongside lifestyle modification and pharmacotherapy, for selected patients with uncontrolled or resistant hypertension. The clinical question is whether RDN provides benefits beyond BP reduction and whether a single intervention is sufficient for BP control. […]

Interventional Treatment of Hypertension: From Renal Denervation to the Next Wave Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

When and How to Use 24-h Ambulatory Blood PressureMonitoring in Patients with CKD

by Prateek Chopra | June 17, 2026 | Cardiology Conferences | ESH 2026 Study Background: Chronic kidney disease (CKD), defined as abnormalities of kidney structure or function persisting ≥3 months, is a growing global burden, ranking as the 10th leading cause of death and a major contributor to cardiovascular mortality. Hypertension is highly prevalent in CKD, and patients frequently exhibit true

When and How to Use 24-h Ambulatory Blood PressureMonitoring in Patients with CKD Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis

by Prateek Chopra | June 17, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Resistant hypertension (RHTN) remains a major clinical challenge. This systematic review and meta-analysis evaluated the blood pressure-lowering efficacy and hypertension control rates achieved after the addition of pharmacological or device-based interventions (e.g., renal denervation, RDN) in patients with true RHTN. Study Design: Key Findings: Clinical Implications:

Blood Pressure Lowering Effects of Pharmacological and Device Based Interventions for Resistant Hypertension: A Systematic Review and Meta-Analysis Read Post »

Leave a Comment / ESH Day 4 / / / , , , ,

The OPTIMAL-HT Study – Evaluation of Triple Single-Pill Combination Therapy in Achieving Stringent Blood Pressure Targets

by Prateek Chopra | June 10, 2026 | Cardiology Conferences | ESH 2026 Treatment Challenge: The 2018 ESC/ESH guidelines introduced stricter systolic BP targets (120–129 mmHg) and stepwise escalation from dual to triple therapy. Evidence for achieving <130 mmHg in patients on ≥3 antihypertensive drugs remains limited. The OPTIMAL-HT study evaluates triple single-pill combination therapy (SPC) for stringent BP control and

The OPTIMAL-HT Study – Evaluation of Triple Single-Pill Combination Therapy in Achieving Stringent Blood Pressure Targets Read Post »

Leave a Comment / ESH Day 2 / / / , , , ,

Low-dose Combinations with 3 or 4 Blood Pressure-LoweringMedications for the Treatment of Hypertension

by Prateek Chopra | June 5, 2026 | Cardiology Conferences | ESH 2026 Study Objective: Evaluate early low-dose triple and quadruple antihypertensive therapy versus stepwise monotherapy across diverse ethnic populations, synthesizing evidence from six landmark RCTs: QUARTET (n=591), TRIUMPH (n=700), QUADRO (n=183), Trident Trial (~1,670), VERONICA (n=300), and CREOLE (n=728). Outcomes included BP reduction, hypertension control, tolerability, and fourth-agent selection in

Low-dose Combinations with 3 or 4 Blood Pressure-LoweringMedications for the Treatment of Hypertension Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism?

by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Context: Non-steroidal mineralocorticoid receptor antagonists (MRAs) and aldosterone synthase inhibitors (ASIs) are emerging therapeutic approaches in primary aldosteronism (PA). Evidence from randomized trials, single-arm studies, real-world analyses, and ongoing clinical programs evaluates the efficacy, biochemical outcomes, and safety of finerenone, baxdrostat, and dexfadrostat. Key Evidence – MRAs:

Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors: Competitors or Allies in Primary Aldosteronism? Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,

Renal Denervation for Resistant Hypertension in CKD and ESRD: ESH 2026 Clinical Update

by Prateek Chopra | June 4, 2026 | Cardiology Conferences | ESH 2026 Clinical Rationale: Renal denervation (RDN) is being evaluated as an adjunctive therapy for patients with advanced CKD, end-stage renal disease (ESRD), and resistant hypertension. Current evidence is drawn from ESH/ESC recommendations, sham-controlled randomized trials, registries, observational studies, and ongoing clinical protocols. Current Recommendations: Key Evidence: Emerging Applications: Renal

Renal Denervation for Resistant Hypertension in CKD and ESRD: ESH 2026 Clinical Update Read Post »

Leave a Comment / ESH Day 1 / / / , , , ,
Scroll to Top